Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 23Completed 13Unknown 12Not yet recruiting 9Active not recruiting 5Terminated 4Withdrawn 1Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 6Genitourinary 5Breast 3Plasma cell 2Gastrointestinal 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Myeloid 1Lymphoid 1Gynecologic 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 40Cisplatin 37Pemetrexed 33Radiotherapy 23Paclitaxel 22pembrolizumab 20durvalumab 19Docetaxel 19Gemcitabine 18Nivolumab 15Radiosurgery 14Etoposide 13atezolizumab 11Erlotinib Hydrochloride 11Taxes 8Magnetic Resonance Spectroscopy 8Drug Therapy 8Bevacizumab 8Cyclophosphamide 7Platinum 6Gefitinib 6Surveys and Questionnaires 5Biopsy 5130-nm albumin-bound paclitaxel 51,2-diaminocyclohexaneplatinum II citrate 5sotorasib 4Ramucirumab 4Radiation 4Immunotherapy 4Fluorodeoxyglucose F18 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Injections × Thoracic × Clear all
NCT00112060 2014-03-31

A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Spectrum Pharmaceuticals, Inc

Phase 1/2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡